AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for N-lysine methyltransferase KMT5A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NQR1

UPID:

KMT5A_HUMAN

Alternative names:

H4-K20-HMTase KMT5A; Histone-lysine N-methyltransferase KMT5A; Lysine N-methyltransferase 5A; Lysine-specific methylase 5A; PR/SET domain-containing protein 07; SET domain-containing protein 8

Alternative UPACC:

Q9NQR1; A8K9D0; Q86W83; Q8TD09

Background:

N-lysine methyltransferase KMT5A, also known as H4-K20-HMTase KMT5A, plays a pivotal role in epigenetic transcriptional repression by specifically monomethylating 'Lys-20' of histone H4 (H4K20me1). This modification is crucial during mitosis, signifying a specific tag for silencing euchromatic genes. KMT5A's activity is not limited to histones; it also monomethylates non-histone proteins, including p53/TP53, thereby repressing p53/TP53-target genes. Its function is essential for cell proliferation, chromosome condensation, and proper cytokinesis.

Therapeutic significance:

Understanding the role of N-lysine methyltransferase KMT5A could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.